Drug Markets/Upadacitinib

Upadacitinib

3 NDCs across 1 manufacturer|0 Generic,3 Brand

Upadacitinib is used to treat rheumatoid arthritis, per the National Library of Medicine's MED-RT classification.

▸ More about this market

The brand product was first FDA-approved on Aug 16, 2019. In 2024, Medicare Part D spent $1.4 billion on Upadacitinib across 194,000 claims for 29,000 beneficiaries.

Upadacitinib is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $229.24 to $459.41 per EAthe most expensive product costs about 2.0× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

3

0G / 3B

Manufacturers

1

competing in market

Price Spread

$229.24 – $459.41

per EA

7d Activity

30 flat

avg +0.2% WoW · of 3 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Manufacturer Breakdown

1 manufacturer producing UPADACITINIB

Drug Portfolio

3 NDCs total, 3 shown

Drug Price 7d Change
RINVOQ ER 45 MG TABLET
$459.4143
per EA
+0.04%
RINVOQ ER 15 MG TABLET
$229.2749
per EA
+0.15%
RINVOQ ER 30 MG TABLET
$229.2366
per EA
+0.28%

Frequently Asked Questions

What is Upadacitinib used to treat?

Upadacitinib is used to treat rheumatoid arthritis, per the National Library of Medicine's MED-RT classification.

How much does Medicare spend on Upadacitinib?

In 2024, Medicare Part D spent $1.4 billion on Upadacitinib across 194,000 claims for 29,000 beneficiaries.

How many Upadacitinib products are on the market?

The Upadacitinib drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.

What is the price range for Upadacitinib?

NADAC reference prices for Upadacitinib range from $229.2366 to $459.4143 per EA — the most expensive product costs about 2.0× the cheapest.

Which manufacturers make Upadacitinib?

1 manufacturer lists Upadacitinib in NADAC. Ranked by number of NDCs, the largest are AbbVie Inc. (3).

How has the price of Upadacitinib changed recently?

Over the past 7 days, 3 Upadacitinib NDCs rose and 0 fell, with a market-wide average change of +0.2%.